Featured
-
-
-
-
-
Research Highlight |
Activity of selpercatinib in RET fusion-positive cancers confirmed
- Diana Romero
-
-
Correspondence |
Time for a change and to adopt a novel molecular genomic approach in NETs
- Lisa Bodei
- , Eric Liu
- & Ronald R. Salem
-
Correspondence |
Reply to ‘Time for a change and to adopt a novel molecular genomic approach in NETs’
- Guido Rindi
- & Bertram Wiedenmann
-
Review Article |
Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned
Broad population screening of asymptomatic individuals for cancers of the prostate or thyroid has resulted in overdiagnosis and overtreatment. Herein, the authors describe the epidemiology, pathology, and screening guidelines for the management of patients with those cancers, and discuss existing international active surveillance protocols.
- Lisa M. Lowenstein
- , Spyridon P. Basourakos
- & Jeri Kim
-
News & Views |
Neuroendocrine neoplasia goes molecular — time for a change
In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
- Guido Rindi
- & Bertram Wiedenmann
-
Consensus Statement
| Open AccessThe biology and treatment of Merkel cell carcinoma: current understanding and research priorities
Merkel cell carcinoma (MCC) is a rare and aggressive form of nonmelanoma skin cancer. The availability of immune checkpoint inhibition has improved the outcomes of a subset of patients with MCC, although many unmet needs continue to exist. In this Consensus Statement, the authors summarize developments in our understanding of MCC while also providing consensus recommendations for future research.
- Paul W. Harms
- , Kelly L. Harms
- & Isaac Brownell
-
Research Highlight |
Precision medicine for ATC — BRAF and MEK inhibition shows promise
- David Killock
-
Review Article |
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The receptor-tyrosine kinase RET has been identified as a potentially actionable driver of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, but have only modest efficacy in patients with thyroid cancers, mostly in those withRET mutations, or RET-rearranged lung cancers. Herein, the authors outline the aberrations in RET that contribute to tumorigenesis, review the current clinical data for inhibitors of this kinase, and discuss whether the limited clinical success achieved with these agents to date is attributable to the intractability of RET as a drug target or the lack of highly specific RET inhibitors.
- Alexander Drilon
- , Zishuo I. Hu
- & Daniel S. W. Tan
-
-
-
-
Editorial |
Key advances: translation and location
-
Year in Review |
Defining rules for increasingly personalized treatments
In 2016, results of an extensive trial broadened the range of malignancies that can be treated with everolimus to include neuroendocrine tumours (NETs) of the lung and gastrointestinal tract. Furthermore, studies aimed at identifying biomarkers with increased specificity, and at better defining high-grade NETs have enabled substantial progress towards delivering effective targeted treatments to patients with NETs.
- Massimo Falconi
- & Stefano Partelli
-
-
-
-
Review Article |
Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms
Contrary to other cancer types, histopathology remains the mainstay of diagnosis and classification of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Increasing knowledge of the molecular genetics and biology of GEP-NENs promises to improve classification of disease subtypes, and thus the management of the disease. Herein, the authors discuss the features of GEP-NENs that, as prognostic or predictive biomarkers, could form the basis for a novel, clinically useful molecular classification system.
- Mark Kidd
- , Irvin Modlin
- & Kjell Öberg
-
Review Article |
Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease
Patients with von Hippel–Lindau (VHL) disease are susceptible to a range of neoplasms. More than 50% of these patients suffer from a range of pancreatic lesions at some point in their lifetime, and the different types of lesions require different management approaches. In this Review, the authors describe the types of pancreatic lesions that are associated with VHL disease, and discuss the management of patients with different pancreatic manifestations; an overall patient-management algorithm is also presented.
- Xavier M. Keutgen
- , Pascal Hammel
- & Electron Kebebew
-
Review Article |
Evolving molecularly targeted therapies for advanced-stage thyroid cancers
Advances in our understanding of thyroid cancer biology have led to the regulatory approval of a number of molecularly targeted therapies for advanced-stage disease. Herein, the authors summarize the progress made to date in molecular medicine for the different histotypes of thyroid cancer, and highlight the questions for future research focused on treatment of the various disease subtypes.
- Keith C. Bible
- & Mabel Ryder
-
-
-
-
-
-
-
-
In Brief |
Sorafenib shows efficacy in thyroid cancer
-
-
News & Views |
Radioiodine in thyroid cancer—how to minimize side effects
Life expectancy of most patients with differentiated thyroid cancer is normal, so adverse treatment effects should be minimized. Lower activities of radioiodine for ablation of thyroid remnants are non-inferior to higher activities and quality of life can be maintained by preparation of radioiodine remnant ablation using recombinant human thyrotropin.
- Christoph Reiners
- & Markus Luster
-
-
-
Research Highlight |
Radiopeptide therapy improves outcomes for neuroendocrine cancers
- Lisa Hutchinson
-
-
-